U.S. FDA approved Merck & Co., Inc.’s Steglujan Tablets for the treatment of Type 2 Diabetes
U.S. FDA (Food and Drug Administration) recently approved Merck & Co., Inc.’s Steglujan (ertugliflozin and sitagliptin) Tablets for the treatment of Type 2 Diabetes
Company: Merck & Co., Inc.
Brand Name: Steglujan
Treatment for: Diabetes Type 2
Dosage Form: Tablets
Generic name: ertugliflozin and sitagliptin
General information about Balcoltra
Steglujan (ertugliflozin and sitagliptin) is a sodium glucose co-transporter 2 (SGLT2) inhibitor, and dipeptidyl peptidase-4 (DPP-4) inhibitor combination used to improve glycemic control in adults with type 2 diabetes.
Steglujan is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus when treatment with both ertugliflozin and sitagliptin is appropriate. Steglujan is not recommended in patients with type 1 diabetes mellitus or for the treatment of diabetic ketoacidosis.